您现在的位置是:UK first to approve Casgevy gene therapy for blood disorders >>正文
UK first to approve Casgevy gene therapy for blood disorders
上海品茶网 - 夜上海最新论坛社区 - 上海千花论坛85755人已围观
简介By subscribing, you agree to our Terms of Use and Policies You may unsubscribe at any time.Recently,...
By subscribing, you agree to our Terms of Use and Policies You may unsubscribe at any time.
Recently, scientists aiming to devise a one-time treatment to relieve symptoms and possibly cure genetic diseases have successfully found a solution.
A new study reported the development of Casgevy, a gene-editing tool made using CRISPR-Cas9 to treat two severe blood conditions – sickle-cell disease and β-thalassaemia. The process involves editing genes that encode hemoglobin in blood-producing stem cells.
UK medicines regulator – Medicines and Healthcare Products Regulatory Agency (MHRA) is the first to approve this therapy, following the success of clinical trials.
Prospects to employ future CRISPR therapies
Kay Davies, a geneticist at the University of Oxford, stated: “This is a landmark approval which opens the door for further applications of CRISPR therapies in the future for the potential cure of many genetic diseases.”
See Also Related- CRISPR-like system capable of editing human genome uncovered in eukaryotes
- Everything You Ever Wanted to Know About CRISPR
- CRISPR-based gene editing gets smaller, better "scissors"
- CRISPR Breakthrough: Scientists Can Now Turn Genes On and Off at Whim
According to Nature, the treatment is administered by intravenous infusion. Vertex Pharmaceuticals in Boston, Massachusetts, and CRISPR Therapeutics in Zug, Switzerland, developed the therapy.
Scientists alluding to the success of Casgevy exemplified that the therapy relieved patients of debilitating pain in sickle-cell disease and reduced or eliminated the need for regular blood transfusions in β-thalassaemia.
“The trial for sickle-cell disease has followed 29 out of 45 participants long enough to draw interim results. Casgevy completely relieved 28 of those people of debilitating episodes of pain for at least one year after treatment,” reported Nature.
In the trials for severe β-thalassemia, for which the standard treatment entails monthly blood transfusions. Nature reported that out of 54 individuals receiving Casgevy, 42 participated long enough to yield interim results. Among these, 39 didn't require a blood transfusion for a year, while the remaining three saw a reduction of over 70 percent in transfusion needs.
Revolutionary use of CRISPR-Cas9 tool
The revolutionary aspect of this therapy is its utilization of CRISPR-Cas9, a tool that won the Nobel Prize in Chemistry in 2020, to precisely edit genes in blood-producing stem cells.
By targeting a particular gene – BCL11A, Casgevy triggers the production of fetal hemoglobin, which can alleviate symptoms by improving oxygen supply to tissues.
However, clinical trials observed certain side effects in participants, including nausea and fever, but major safety concerns were undetected.
However, scientists noted concerns about potential unintended genetic modifications by CRISPR-Cas9, which are being monitored.
David Rueda, a geneticist at Imperial College London, told the SMC stated:
“It is well known that CRISPR can result in spurious genetic modifications with unknown consequences to the treated cells. It would be essential to see the whole-genome sequencing data for these cells before concluding. Nonetheless, this announcement makes me feel cautiously optimistic.”
Other countries, including the US and Europe, are reviewing Casgevy for approval. However, the high cost and complex technology involved might limit its accessibility, especially in low- and middle-income countries.
Calculations indicate that the therapy might cost around US$2 million per patient, posing a substantial accessibility limitation.
“The challenge is that these therapies will be very expensive, so a way of making these more accessible globally is key,” Davies noted.
A Vertex representative told Nature: “We have not established a list price for the UK at this time and are focused on working with the health authorities to secure reimbursement and access for eligible patients as quickly as possible.”
Tags:
转载:欢迎各位朋友分享到网络,但转载请说明文章出处“上海品茶网 - 夜上海最新论坛社区 - 上海千花论坛”。http://www.jz08.com.cn/news/647373.html
相关文章
Blockchain company NvirWorld signs MOU with World Vision: Donate to the earthquake in Turkey
UK first to approve Casgevy gene therapy for blood disordersSingapore, Singapore, 18th February, 2023, ChainwireNvirWorld – a blockchain technology innova...
阅读更多
Bitcoin price surges to $26K as bulls react to CPI data
UK first to approve Casgevy gene therapy for blood disordersBitcoin price hit highs of $26,553 on Coinbase, with 16% upside in 24 hours.US inflation data showed...
阅读更多
Crypto, stocks fall as Powell hints at higher rates
UK first to approve Casgevy gene therapy for blood disordersCrypto and stocks reacted negatively to comments about US inflation by Fed Chair Jerome Powell.Bitco...
阅读更多
热门文章
- Consensys Announces Mobile App for Ethereum Wallet MetaMask
- ETHUSD soared to a new high for the year, and the move was unrelated to the US dollar.
- Bulls Defend $10k But A Dip To $9,700 Remains Likely
- Memeinator raises over $750k as the stage
- Bitcoin Represents Future Of Online Security: Twitter CEO
- 12 of the Best Best Cheap Cryptos to Buy Now
最新文章
Maison Hennessy Announces The Launch Of Web3 Platform H3nsy
Is it safe to buy the Voyager Digital token (VGX) rally?
AllianceBlock partners with ABO Digital for structured crypto projects financing
Crypto.com offers Aston Martin F1 merch pack ahead of Mexico GP
Metacade presale stage 5 selling out as strategic partnership with MEXC is confirmed
Cosmos proposal to cap ATOM inflation rate at 10% passed